Lv1
48 积分 2024-05-13 加入
Fixed-duration ibrutinib–venetoclax versus chlorambucil–obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial
1天前
待确认
Integrative Multi-omics Approaches for Cancer Therapeutics
8天前
已关闭
Epidemiology of Sjögren syndrome
16天前
已完结
Age-standardized incidence, prevalence, mortality rates and future projections of autoimmune diseases in China: a systematic analysis based on GBD 2021
16天前
已完结
Pathogenesis of autoimmune disease
16天前
已完结
Report of Consensus Panel 3 from the 12th International Workshop on Waldenström's Macroglobulinemia on the Management of Patients with High-Risk Disease
20天前
已关闭
Building the Future Management of Follicular Lymphoma with T-Cell-Redirecting Strategies
26天前
已完结
Two‐year follow‐up of relmacabtagene autoleucel in relapsed or refractory follicular lymphoma in RELIANCE study
26天前
已完结
Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study
27天前
已完结
Loncastuximab tesirine with rituximab in patients with relapsed or refractory follicular lymphoma: a single-centre, single-arm, phase 2 trial
28天前
已完结
皖公网安备34019202002308
